Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome
-
Published:2024-01-27
Issue:2
Volume:73
Page:
-
ISSN:1432-0851
-
Container-title:Cancer Immunology, Immunotherapy
-
language:en
-
Short-container-title:Cancer Immunol Immunother
Author:
Cheng Debin,Zhang Zhao,Liu Dong,Mi Zhenzhou,Tao Weidong,Fu Jun,Fan Hongbin
Abstract
Abstract
Osteosarcoma (OS) represents a profoundly invasive malignancy of the skeletal system. T cell exhaustion (Tex) is known to facilitate immunosuppression and tumor progression, but its role in OS remains unclear. In this study, single-cell RNA sequencing data was employed to identify exhausted T cells within the tumor immune microenvironment (TIME) of OS. We found that exhausted T cells exhibited substantial infiltration in OS samples. Pseudotime trajectory analysis revealed a progressive increase in the expression of various Tex marker genes, including PDCD1, CTLA4, LAG3, ENTPD1, and HAVCR2 in OS. GSVA showed that apoptosis, fatty acid metabolism, xenobiotic metabolism, and the interferon pathway were significantly activated in exhausted T cells in OS. Subsequently, a prognostic model was constructed using two Tex-specific genes, MYC and FCGR2B, which exhibited exceptional prognostic accuracy in two independent cohorts. Drug sensitivity analysis revealed that OS patients with a low Tex risk were responsive to Dasatinib and Pazopanib. Finally, immunohistochemistry verified that MYC and FCGR2B were significantly upregulated in OS tissues compared with adjacent tissues. This study investigates the role of Tex within the TIME of OS, and offers novel insights into the mechanisms underlying disease progression as well as the potential treatment strategies for OS.
Graphic Abstract
Funder
Natural Science Foundation of Shaanxi Province National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference43 articles.
1. Hamre MR, Severson RK, Chuba P, Lucas DR, Thomas RL, Mott MP (2002) Osteosarcoma as a second malignant neoplasm. Radiother Oncol 65(3):153–157. https://doi.org/10.1016/s0167-8140(02)00150-0 2. Chen Y, Liu R, Wang W, Wang C, Zhang N, Shao X, He Q, Ying M (2021) Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacol Res 169:105684. https://doi.org/10.1016/j.phrs.2021.105684 3. Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W (2021) Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent. Cancer Lett 500:1–10. https://doi.org/10.1016/j.canlet.2020.12.024 4. Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, Tang L, Zhang J, Yin J, Huang Y, Yu W, Wang Y, Zhou C, Su Y, He A, Sun Y, Shen Z, Qian B, Meng W, Fei J, Yao Y, Pan X, Chen P, Hu H (2020) Single-cell rna landscape of intratumoral heterogeneity and immunosuppressive. Nat Commun 11(1):6322. https://doi.org/10.1038/s41467-020-20059-6 5. Fernández L, Metais J, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, Martínez J, Leung W, Pérez-Martínez A (2017) Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells. Clin Cancer Res 23(19):5824–5835. https://doi.org/10.1158/1078-0432.CCR-17-0075
|
|